Literature DB >> 2185040

Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome.

R L Rosenfield1, R B Barnes, J F Cara, A W Lucky.   

Abstract

Polycystic ovarian syndrome (PCOS) appears to be due to a previously unrecognized type of steroidogenic abnormality, one in which hyperandrogenism arises from a regulatory abnormality (dysregulation) rather than from enzyme deficiency. It appears that PCOS typically arises from masculinized regulation of the androgen-forming enzyme (cytochrome P450c17 alpha) within ovarian thecal cells. This may arise by either excessive stimulation by luteinizing hormone (LH) or by escape from desensitization to LH. We review evidence which is compatible with the concept that the latter situation may result from an intrinsic intraovarian flaw in the paracrine feedback mechanism by which thecal androgen biosynthesis is inhibited and that coexistent adrenal 17-ketosteroid hyper-responsiveness to corticotropin (ACTH) may be due to a similar type of dysregulation of adrenocortical P450c17 alpha.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2185040

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  40 in total

1.  Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome.

Authors:  Marcus A Rosencrantz; Mickey S Coffler; Annette Haggan; Kimberly B Duke; Michael C Donohue; Rana F Shayya; H Irene Su; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2011-01-26       Impact factor: 5.958

Review 2.  Genetics of ovarian disorders: polycystic ovary syndrome.

Authors:  Stephen Franks; Mark McCarthy
Journal:  Rev Endocr Metab Disord       Date:  2004-03       Impact factor: 6.514

3.  Hirsutism.

Authors:  G S Conway; H S Jacobs
Journal:  BMJ       Date:  1990-09-29

Review 4.  Attenuation of hyperinsulinemia in polycystic ovary syndrome: what are the options?

Authors:  D A Ehrmann
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 5.  In vitro fertilization treatment in patients with polycystic ovaries.

Authors:  A Shulman; J Dor
Journal:  J Assist Reprod Genet       Date:  1997-01       Impact factor: 3.412

6.  CYP17 gene analysis in hyperandrogenised women with and without exaggerated 17-hydroxyprogesterone response to ovarian stimulation.

Authors:  M Liović; J Prezelj; A Kocijancic; G Majdic; R Komel
Journal:  J Endocrinol Invest       Date:  1997-04       Impact factor: 4.256

Review 7.  Mechanisms of intergenerational transmission of polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Luis R Hoyos; Gregorio D Chazenbalk; Rajanigandha Naik; Vasantha Padmanabhan; David H Abbott
Journal:  Reproduction       Date:  2020-01       Impact factor: 3.906

Review 8.  Nutrition, hormones, and breast cancer: is insulin the missing link?

Authors:  R Kaaks
Journal:  Cancer Causes Control       Date:  1996-11       Impact factor: 2.506

Review 9.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

10.  Relationship between 17-hydroxyprogesterone responses to human chorionic gonadotropin and markers of ovarian follicle morphology in women with polycystic ovary syndrome.

Authors:  Kevin H Maas; Sandy S Chuan; Heidi Cook-Andersen; H Irene Su; A Duleba; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.